AFFiRis Shows Potential Of AD04 As First Disease Modifier For People With Alzheimer’s Disease In Phase II Clinical Study
AFFiRis has announced that ADO4 is the first ever drug to demonstrate disease modifying properties in Alzheimer’s patients. The phase II clinical trial involved over 300 people with Alzheimer’s disease, providing them with different doses of the AD02 and AD04 compound. Results showed that 47 % of the patients stabilized regarding their cognitive/ functional status. The study also showed that this effect was statistically significantly correlated with the rescue of the hippocampus, which is the region of the human brain where cognitive and memory functions are located. Results were more prominent in people with early onset Alzheimer’s disease. This was not a controlled study, with no placebo trial running alongside the clinical trial in people with Alzheimer’s disease
These results for the first time meet all the criteria for disease modifications defined by US and European Regulatory.
Alzheimer’s Society comment:
‘Having a newly tested drug produce seemingly positive results for people with Alzheimer’s disease is promising. This drug targets amyloid in the brain, which is an approach a number of other ongoing studies are also taking. We are yet to see the full set of results from this trial which will give us a better idea of the true promise of this potential treatment. That said, as a minimum we need to see more rigorous further testing of this drug in many more people with the condition to understand whether this really could slow or stop Alzheimer’s in its tracks.
‘There are few treatments and no cure for dementia which is why Alzheimer’s Society is committed to exploring ways to develop better treatments for dementia. Our Drug Discovery programme is attempting to speed up this process by testing drugs available for other conditions that show promise for different forms of dementia.’
Dr Doug Brown
Director of Research and Development